<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">Pharmaceutical legislation provides a legal framework to ensure the availability of acceptably safe, effective and high-quality medicines to patients. One element of this framework mandates national regulatory authorities (NRAs) and marketing authorisation holders (MAHs) to establish and maintain pharmacovigilance systems (PV systems). These systems should be capable of detecting, assessing, understanding and preventing adverse effects or any other possible drug-related problems [
 <xref ref-type="bibr" rid="CR1">1</xref>].
</p>
